BOULDER, Colo. (PRWEB) October 08, 2014
Fluonic, Inc., will exhibit and present at the fourth annual Partnership Opportunities in Drug Delivery (PODD) conference Oct. 14-15 in Boston.
Fluonic, Inc., is a digital health and information company that provides monitoring of infusion drug delivery with patented flow measurement and control technology. The company’s products solve the problem that the $10 billion drug infusion market cannot accurately measure the flow of medication from infusion pumps to patients, particularly very low flows.
The PODD conference, taking place at the Renaissance Boston Waterfront Hotel, is a meeting place that inspires innovation and advancement of drug development and delivery, and provides support for industry leaders. The strategic-level program for pharma and biotech business development professionals offers a thorough overview of the latest drug delivery technologies available, and an update on deals and opportunities to improve therapies and extend the life cycle of a drug. Drug delivery and specialty pharma companies can present their technologies and obtain the latest insights on delivery and formulation needs.
At PODD, Fluonic will discuss its technology and flagship product, the SURE+ fully disposable infusion system. The system, which measures the actual flow rate to the patient in real time, allows remote monitoring of the infusion procedure, and provides auto adjustments and alarms.
Creating a new standard of care
“The PODD Conference is an excellent opportunity for Fluonic to discuss a cost-effective, scalable solution for a problem plaguing the health care industry for more than 30 years,” says Jim Kasic, CEO of Fluonic. While more than 90 percent of hospitalized patients receive some type of intravenous drug therapy, and hundreds of thousands more receive intravenous drug therapy at home or on an out-patient basis, the pumps that deliver the medication operate blindfolded, unable to verify what they actually deliver to the patient, he explains. The industry is plagued with recalls of hundreds of thousands of faulty pumps.
Fluonic’s sensor, Kasic states, is accurate over the entire flow range, delivers information on the medication flow to designated recipients, wirelessly, and senses very low flows very precisely. As a result, health care providers can better control infusion drug delivery, and patients can receive more types of drugs at home, effectively reducing hospital stays and visits, and outpatient clinic visits. “By eliminating the questions and guesswork from infusion drug therapy, Fluonic can create a new standard of care,”
Fluonic, Inc. (http://www.fluonic.com)
Based in Boulder, Colo., Fluonic, Inc., is a digital health and information company that provides monitoring of infusion drug delivery with patented flow measurement and control technology. The company’s technology solves the problem that the $10 billion drug infusion market cannot accurately measure the flow of medication from infusion pumps to patients, particularly very low flows. Flagship products and systems include the VeriFlow sensor and SURE+ system, which provides the precision and reliability of durable pumps at the cost of disposables. The company recently received a National Institutes of Health grant supporting a study to demonstrate the applicability of its flow measurement technology to ambulatory insulin delivery.